Sugi Predict

Sugi Predict / Compounds / Ribose (Furanose)

Ribose (Furanose)

Ribose (Furanose)

SCHEMBL3655770

OC[C@H]1OC(O)[C@H](O)[C@@H]1O.c1cncnc1

nearest known ligand 0.44

Full drug profile on Sugi Atlas →

Predicted protein targets (top 13)

geneUniProtsupporting neighboursconfidence
▸ MAPT P10636 1/20 0.41
▸ CDA P32320 1/20 0.41
▸ LGALS1 P09382 2/20 0.39
▸ LGALS3 P17931 2/20 0.39
▸ LGALS9 O00182 1/20 0.39
▸ LGALS8 O00214 1/20 0.39
▸ OGA O60502 1/20 0.38
▸ HEXA P06865 1/20 0.38
▸ HEXB P07686 1/20 0.38
▸ ADA P00813 1/20 0.37
▸ TYR P14679 1/20 0.37
▸ HK1 P19367 1/20 0.36
▸ HK2 P52789 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Ribose (Furanose) SCHEMBL7051560 1.00 MAPT (0.41) MAPTCDALGALS1LGALS3LGALS9
Ribose (Furanose) SCHEMBL10818882 1.00 MAPT (0.41) MAPTCDALGALS1LGALS3LGALS9
Ribose (Furanose) SCHEMBL7511471 1.00 MAPT (0.41) MAPTCDALGALS1LGALS3LGALS9
Ribose (Furanose) SCHEMBL18788526 0.88 MAPT (0.41) MAPTCDALGALS1LGALS3LGALS9
Dextrose SCHEMBL28143229 0.81 LGALS1 (0.52) LGALS1LGALS3LGALS9LGALS8HK1
B-D-Galactose SCHEMBL27766291 0.81 LGALS1 (0.52) LGALS1LGALS3LGALS9LGALS8HK1
Beta-D-Glucose SCHEMBL27745359 0.81 LGALS1 (0.52) LGALS1LGALS3LGALS9LGALS8HK1
B-D-Galactose SCHEMBL28251165 0.81 LGALS1 (0.52) LGALS1LGALS3LGALS9LGALS8HK1
Ribose (Furanose) SCHEMBL23017520 0.80 LGALS1 (0.54) LGALS1LGALS3LGALS9LGALS8
Ribose (Furanose) SCHEMBL77096 0.80 LGALS1 (0.54) LGALS1LGALS3LGALS9LGALS8

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 35 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20100311683-A1 CYTIDINE ANALOGS FOR TREATMENT OF MYELODYSPLASTIC SYNDROMES CELGENE CORPORATION 2010-12-09 — — US claimed
EP-2211870-A1 CYTIDINE ANALOGS FOR TREATMENT OF MYELODYSPLASTIC SYNDROMES CELGENE CORPORATION (US) 2010-08-04 — — EP claimed
US-20090318556-A1 BIOMARKERS FOR DETECTING RADIATION EXPOSURE: METHODS AND USES THEREOF THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES 2009-12-24 — — US claimed
WO-2009058394-A1 CYTIDINE ANALOGS FOR TREATMENT OF MYELODYSPLASTIC SYNDROMES CELGENE CORPORATION (US) 2009-05-07 — — WO claimed
WO-2008028193-A2 COLON-TARGETED ORAL FORMULATIONS OF CYTIDINE ANALOGS PHARMION CORPORATION (US) 2008-03-06 — — WO claimed
US-20080057086-A1 COLON-TARGETED ORAL FORMULATIONS OF CYTIDINE ANALOGS PHARMION CORPORATION (US) 2008-03-06 — — US claimed
CN-1671398-A Compositions and methods for treating epithelia and retinal tissue diseases INSPIRE PHARMACEUTICALS INC (US) 2005-09-21 — — CN claimed
EP-0971944-A4 ANTI-VIRAL GUANOSINE-RICH TETRAD FORMING OLIGONUCLEOTIDES ARONEX PHARMACEUTICALS INC (US) 2005-01-26 — — EP claimed
EP-0971944-A1 ANTI-VIRAL GUANOSINE-RICH TETRAD FORMING OLIGONUCLEOTIDES Aronex Pharmaceuticals, Inc. (US) 2000-01-19 — — EP claimed
WO-1998033807-A9 ANTI-VIRAL GUANOSINE-RICH TETRAD FORMING OLIGONUCLEOTIDES — 1999-01-28 — — WO claimed
WO-1998033807-A1 ANTI-VIRAL GUANOSINE-RICH TETRAD FORMING OLIGONUCLEOTIDES ARONEX PHARMACEUTICALS, INC. (US) 1998-08-06 — — WO claimed
WO-2019079259-A1 METHODS FOR TREATING CONTRACTURED MUSCLE AND RELATED CULTURED CELLS REHABILITATION INSTITUTE OF CHICAGO d/b/a Shirley Ryan AbilityLab (US) 2019-04-25 — — WO disclosed
US-20190112580-A1 METHODS FOR TREATING CONTRACTURED MUSCLE AND RELATED CULTURED CELLS REHABILITATION INSTITUTE OF CHICAGO d/b/a Shirley Ryan AbilityLab (US) 2019-04-18 — — US disclosed
CN-107406854-A RNA-guided eradication of human JC virus and other polyomaviruses 英联邦高等教育系统天普大学 2017-11-28 — — CN disclosed
WO-2013022872-A1 GENE METHYLATION BIOMARKERS AND METHODS OF USE THEREOF CELGENE CORPORATION (US) 2013-02-14 — — WO disclosed
US-5726302-A SUBSTITUTED 4-AMINO PYRROLO(2,3-D) PYRIMIDINE AND PYRAZOLO(3,4-D) PYRIMIDINE NUCLEOSIDE ANALOGS GENSIA INC. (US) 1998-03-10 — — US disclosed
US-5625057-A ANTIVIRAL AJINOMOTO CO., INC. (JP) 1997-04-29 — — US disclosed
WO-1996040707-A1 WATER-SOLUBLE ADENOSINE KINASE INHIBITORS GENSIA SICOR (US) 1996-12-19 — — WO disclosed
US-4299823-A TREATMENT OF COCCIDIOSIS BURROUGHS WELLCOME CO. (US) 1981-11-10 — — US disclosed
US-4299824-A TREATMENT OF COCCIDIOSIS BURROUGHS WELLCOME CO. (US) 1981-11-10 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100311683-A1 CYTIDINE ANALOGS FOR TREATMENT OF MYELODYSPLASTIC SYNDROMES DCTD, CDA, ENTPD1 MAPT 4878/4885CDA 2/4885LGALS1 2425/4885
US-20090318556-A1 BIOMARKERS FOR DETECTING RADIATION EXPOSURE: METHODS AND USES THEREOF OGG1, UNG, HPRT1 MAPT 2696/4885CDA 818/4885LGALS1 398/4885
US-20080057086-A1 COLON-TARGETED ORAL FORMULATIONS OF CYTIDINE ANALOGS MKI67, MTHFD1, AZI2 MAPT 4292/4885CDA 4/4885LGALS1 1300/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.